Background. The aim of this study was to show that sequential intravenous and oral moxifloxacin monotherapy (400 mg once per day) is as efficacious and safe as a combination regimen (intravenous ceftriaxone, 2 g once per day, plus sequential intravenous and oral levofloxacin, 500 mg twice per day) in patients hospitalized with community-acquired pneumonia.
confirmed the efficacy of moxifloxacin in the treatment of mildto-moderate CAP [5] [6] [7] [8] [9] [10] [11] [12] , but data demonstrating its use in patients with more serious disease requiring hospitalization are limited.
The primary purpose of this study was to show that sequential intravenous and oral moxifloxacin monotherapy (400 mg once per day) is safe and effective in hospitalized patients who have CAP with a Pneumococcal Severity Index (PSI) class III-V and who require intravenous antimicrobial therapy. More than one-half of the patients enrolled in the study had CAP with a PSI of IV or V. The study was not designed specifically to assess patients who required treatment in the intensive care unit (ICU). The comparator treatment for this noninferiority trial, a combination regimen (intravenous ceftriaxone, 2 g once per day, plus sequential intravenous and oral levofloxacin, 500 mg twice per day), was chosen after discussions and in accordance with requirements of regulatory authorities.
PATIENTS AND METHODS
Study design and treatment. This prospective, randomized, double-blind multicenter study was designed in accordance with the Consolidating Standards of Reporting Trials (CON-SORT) guidelines to illustrate noninferiority, in terms of efficacy and safety, of sequential intravenous and oral moxifloxacin (400 mg once per day) to a comparator combination therapy consisting of intravenous ceftriaxone (2 g once per day) plus sequential intravenous and oral levofloxacin (500 mg twice per day) for 7-14 days in patients with CAP who were admitted to the hospital (PSI score III-V; 150% of patients had to have a PSI score of IV/V). The study was conducted at 69 centers in 17 countries between January 2004 and July 2005 and in accordance with current guidelines of the International Conference on Harmonization for Good Clinical Practice, the modified Declaration of Helsinki (1996) , and all applicable local laws and regulations. Thirty-one percent of the patients were in southern Europe, 37.6% were in northern Europe, and 31.4% were in Latin America and South Africa. Written consent to participate in the study was obtained prior to enrollment or any study-related procedure (including screening).
Eligible patients were stratified to PSI class III or IV/V. They were then randomly assigned, on the basis of computer-generated lists by Bayer Pharma Biometry, to receive either moxifloxacin or comparator therapy.
The levofloxacin dosage was adjusted in patients with renal impairment, as recommended by the product prescribing information by the hospital pharmacist [13] ; blinding was maintained. No dosage adjustment was made for either ceftriaxone or moxifloxacin. After 3 days of intravenous therapy with either moxifloxacin or levofloxacin, patients could be switched to oral therapy at the discretion of the investigator if the prescribed improvement criteria (reduction in severity and/or number of signs and symptoms of infection) had been fulfilled.
Blinding was achieved by using colored bottles and delivery tubes, as well as placebo infusions; each subject received 3 infusions daily, regardless of study group. To ensure that treatment regimens were indistinguishable during oral therapy, both moxifloxacin and levofloxacin were encapsulated.
Clinical assessment was performed by the investigating physician, and study data were then assessed systematically and blindly by 3 independent committees. The chest radiography committee confirmed that the diagnosis was consistent with pneumonia on the basis of pretherapy radiograph findings. The clinical response committee reviewed data for all patients and reached a unanimous evaluation on clinical response at the assessment time points; deaths were reviewed to determine whether they were caused by pneumonia. The cardiac events committee adjudicated on documented cardiac versus noncardiac events. Undocumented or poorly documented events were classified in terms of probable cardiovascular or noncardiovascular origin.
Patient population. Patients (age, у18 years) with CAP PSI class III-V who required hospitalization and initial intravenous antibiotic therapy were eligible for enrollment in this study. The inclusion and exclusion criteria for the study are shown in Appendix A. Patients were considered to be eligible for clinical efficacy analysis if they met the eligibility criteria, received study drug for у48 h (in cases of clinical failure) or у5 days (in cases of clinical cure), received no other concomitant systemic antimicrobial therapy, had a test-of-cure clinical assessment that was not indeterminate, and had a у80% rate of adherence to study medication. All patients who were randomized, received at least 1 dose of study medication, and underwent 1 observation after the start of the study were included in the intent-to-treat (ITT)/safety population. Patients who met the inclusion criteria for the per-protocol (PP) population but who discontinued study drug because of an adverse event were included in the efficacy analysis.
Clinical and bacteriological evaluation. Clinical signs and symptoms were evaluated before treatment (within 24 h before enrollment), on the day of switch from intravenous to oral therapy, during therapy (3-5 days after start of therapy, if the switch was not undertaken at this time), at the end of treatment (7-14 days after the start of treatment), at test-of-cure assessment (4-14 days after treatment was completed; figure 1), and at the follow-up assessment (21-28 days after treatment was completed). Sputum and blood samples were obtained for culture and susceptibility testing at enrollment and, if clinically indicated, during and at the end of treatment. Acute-and convalescent-phase serum samples were collected for serologic testing for the following atypical organisms at a central laboratory: Chlamydophila pneumoniae (by Chlamydia MIC IgG; Focus Clinical and bacteriological outcome definitions. The primary efficacy outcome was clinical response 4-14 days after completion of study treatment (i.e., the test-of-cure visit) in the PP population, as assessed by the independent review board. Secondary efficacy measurements were clinical and bacteriological response on the day of the switch from intravenous to oral therapy, at the end of treatment, and at the follow-up assessment; bacteriological response at the test-of-cure assessment; mortality attributable to pneumonia at the test-of-cure visit; clinical and bacteriological responses 21-28 days after the test-of-cure visit; and symptom course at each assessment (ITT and PP population). Outcome definitions are shown in Appendix B.
Safety and tolerability assessment. Patients who received at least 1 dose of study drug (i.e., the ITT population) were included in the safety analysis. Adverse events were documented using the Medical Dictionary for Regulatory Activities terminology [14] . Treatment-emergent adverse events and adverse events leading to premature discontinuation of treatment were recorded for intravenous and oral formulations. The incidence and severity of cardiac events were scrutinized by the clinical events committee. Electrocardiography data were recorded before the commencement of therapy, after the first intravenous infusion, and on the third day of therapy for heart rate-corrected QT interval (QT c ) assessment. Mortality was assessed 30 days after the initiation of treatment.
Statistical analysis.
This study was powered to support the primary efficacy objective that sequential intravenous and oral moxifloxacin (400 mg once per day) was noninferior to intravenous ceftriaxone plus sequential intravenous and oral levofloxacin for treatment of CAP with a PSI of III-V on the basis of clinical success at the test-of-cure assessment for the clinically valid population. Sample size was determined to be 304 clinically valid patients in each treatment group on the basis of a predicted failure rate of 15% in the comparator treatment group, an equivalence (clinically relevant) D of 10%, a p (1-sided), and power of 90% (the power calculation in-0.025 cluded an adjustment of 10% to account for the multicenter design of the study). Noninferiority of treatment with moxifloxacin was to be concluded if the lower limit of the 95% CI for cure rate at the test-of-cure visit was greater than Ϫ10% and if the upper 95% CI value was 10. The 95% CI was calculated using Mantel-Haenszel weights reflecting regions and PSI categorization (class III versus IV/V).
In the PP analyses of clinical and bacteriological response, treatment comparisons were performed as "cure" versus "failure"; missing and indeterminate outcomes were excluded from analysis. In the ITT analyses, missing and indeterminate cases were considered to be nonsuccesses.
The 2 treatment groups were compared by univariate analysis with respect to demographic characteristics and characteristics of the infection. The 2 groups were compared by 2-way analysis of variance with respect to bacteriological factors (mixed microbial infection, infection with S. pneumoniae, and bacteremia), septic shock, mechanical ventilation, and lung involvement (bilateral and involvement of 12 lobes) using a CochranMantel-Haenszel test adjusted for center/geographic region. 
RESULTS

Patient disposition and demographic characteristics.
Of the 738 patients randomized in the study, 371 were allocated to the moxifloxacin arm, and 367 were allocated to the comparator arm. Patients excluded from the analyzed populations are shown in figure 2. Of the ITT population, 12 patients had a PSI score of II (and were thus excluded from the PP analysis), 292 had a PSI score of III, 343 had a PSI score of IV, and 86 had a PSI score of V. The PP population consisted of 233 patients with a PSI score of III, 272 patients with a PSI score of IV, and 64 patients with a PSI score of V. Because the aim of this study was to evaluate patients with "serious" CAP (i.e., patients who required intravenous therapy), only patients with PSA scores of III-V were included in the PP population. It was not our intention to study patients with CAP of a severity that required treatment in an ICU (only 9.6% of the clinically valid patients were admitted to the ICU).
Baseline demographic and medical characteristics for the clinically valid population were similar between the 2 groups (table 1). As expected in this population of hospitalized patients with pneumonia, a substantial number (89 [30.6%] in the moxifloxacin arm and 90 [32.4%] in the comparator arm) had cardiac comorbidities. The median duration of intravenous therapy was 5 days for the moxifloxacin arm and 6 days for the comparator arm (mean, 6.1 vs. 6.6 days;
, by Wil-P p .121 coxon 2-sample test). Overall, 77% of patients were switched from intravenous to oral therapy; the mean duration of oral therapy (‫ע‬SD) was days in both groups. The median 7.0 ‫ע‬ 2.5 duration of exposure to moxifloxacin (intravenous and oral) was 11 days, whereas the median exposure to the comparator was 12 days (mean, 11.2 vs. 11.6 days;
, by Wilcoxon P p .070 2-sample test).
Clinical cure and clinical success rates. At the test-of-cure assessment, the clinical cure rates for the clinically valid population were 86.9% for the moxifloxacin group and 89.9% for the comparator group (95% CI for the difference between the 2 clinical success rates, Ϫ8.1 to 2.2; primary end point). Subpopulation analyses that included patients stratified by PSI All primary system organ classes and medical histories with a frequency of у5% in either treatment group. c Subjects were considered to be hypoxic if 1 of the following criteria was met: while breathing room air, subjects had an arterial partial pressure of oxygen !60 mm Hg or oxygen saturation !90%; subjects were in an ICU; or subjects were undergoing mechanical ventilation.
score and those with pneumonia caused by S. pneumoniae or an atypical organism revealed similar clinical cure rates for the 2 treatment groups (table 2). Clinical success rates in patients with pneumonia due to L. pneumophila were 90.0% (9 of 10 patients) and 75.0% (9 of 12 patients) in the moxifloxacin and comparator arms, respectively.
Clinical improvement (defined as a reduction in the severity and/or number of signs and symptoms of infection) occurred in 91.8% of patients in the moxifloxacin arm and 93.5% of those in the comparator arm (95% CI, Ϫ5.8 to 2.8) at the during-therapy assessment (3-5 days after the start of therapy). At follow-up (21-28 days after treatment), of the patients who had clinical success at the test-of-cure visit, cure was maintained in 96.0% of patients in the moxifloxacin arm and 97.2% of those in the comparator arm (95% CI, Ϫ2.8 to 1.1). The noninferiority of moxifloxacin was also confirmed in the ITT population; at the test-of-cure assessment, the clinical cure rates were 79.6% for the moxifloxacin arm and 83.8% for the comparator arm (95% CI, Ϫ9.7 to 1.4).
Mortality. There was no significant difference in 30-day mortality overall or in the different PSI strata between the 2 treatment groups: 18 patients (4.9%) in the moxifloxacin group died, compared with 12 (3.3%) in the comparator group (table  3) . Of the patients who died, 6 patients in the moxifloxacin arm and 2 in the comparator arm died during the first 72 h of treatment. According to committee evaluation, the 72-h to 30-day mortality rates were 2.4% and 1.4% in the moxifloxacin and comparator arms, respectively ( ). All deaths at-P p .29 tributable to pneumonia except 1 (in the comparator group) involved patients with a PSI risk class of IV or V. For 1 subject in each group, evaluation of the cause of death was not possible because of an underlying condition.
Bacteriological outcomes. Baseline culture results for the patients with microbiologically documented and microbiologically valid CAP are shown in table 4. S. pneumoniae was the causative pathogen in 11.0% (moxifloxacin arm) and 16.2% (comparator arm) of patients in the microbiologically valid population. The rates of bacteriological success (defined as eradication or presumed eradication of the causative pathogen) in the microbiologically valid population at the test-of-cure assessment were 83.3% in the moxifloxacin arm and 85.1% in the comparator arm (95% CI, Ϫ15.4 to 11.8).
The rate of bacteriological success for patients with microbiologically valid CAP with S. pneumoniae infection was 84.4% in both treatment arms. All patients who were clinically cured at the test-of-cure assessment were judged to be bacteriological successes. Susceptibility testing of all S. pneumoniae strains isolated before antibiotic therapy was started was performed in accordance with CLSI standards; all isolates were susceptible to moxifloxacin, and no S. pneumoniae isolate possessed a typical first-step mutation in Ser79 of parC or Ser81 of gyrA. (I. Knezevic, personal communication).
Safety and tolerability. There were no significant differ- ences in the frequency of adverse events, premature discontinuation of therapy, or duration of hospitalization between the moxifloxacin and comparator groups (table 5). In the valid for safety population, 208 subjects (56.5%) in the moxifloxacin arm and 193 subjects (52.9%) in the comparator arm had у1 treatment-emergent adverse events. The most frequent Medical Dictionary for Regulatory Activities categories in the moxifloxacin and comparator arms were, respectively, "investigations" (16.3% vs. 15.3%), "gastrointestinal disorders" (15.5% vs. 15.1%), and "infections and infestations" (including pneumonia as treatment failure; 14.7% vs. 13.2%). The most common single adverse event was diarrhea (8.4% in the moxifloxacin arm and 4.1% in the comparator arm). Stool cultures for Clostridium difficile and tests for toxin were not performed routinely, and only 1 case of C. difficile-associated diarrhea was reported (in the comparator arm). The incidences of adverse events that could be considered a clinical surrogate for QT c prolongation (e.g., cardiac arrest, ventricular tachycardia, and sudden death) were similar in the 2 treatment groups: 2.2% (8 patients) for the moxifloxacin arm and 1.9% (7 patients) for the comparator arm. Of these events, 1 (ventricular tachycardia) in the comparator group was considered to be drug related.
The incidence of adverse events resulting in premature discontinuation of treatment was low in both treatment groups: 29 patients (7.0%) in the moxifloxacin arm and 17 patients (4.7%) in the comparator arm.
DISCUSSION
This prospective, randomized, double-blind study demonstrated that sequential intravenous and oral moxifloxacin monotherapy (400 mg once per day) was noninferior to intravenous ceftriaxone once per day plus sequential intravenous and oral levofloxacin twice per day for the treatment of hos- pitalized patients with CAP who require intravenous antimicrobial therapy and whose infection was classified as PSI III-V. This study was not designed to assess efficacy in patients admitted to the ICU; thus, no specific conclusions are made for this subgroup of patients. Serious comorbidities contributed to the high PSI scores for the 40% of patients included in the study who were aged !65 years. Overall rates of clinical cure, bacteriological success, and mortality were similar between the 2 treatment groups. There were no statistically significant differences in the incidence of adverse events, including those considered to be relevant clinical outcomes of QT c prolongation, between the 2 treatment groups, with the exception of diarrhea, which occurred in 31 patients (8.4%) in the moxifloxacin arm and 15 patients (4.1%) in the comparator arm.
There was 1 case of C. difficile-associated diarrhea in the comparator arm. The rate of occurrence of diarrhea is consistent with previous studies of moxifloxacin-treated patients (4.7%-8.5%) [5, 6, 10, 15, 16] . The study was designed to be rigorously controlled. It used independent committees of experts to assess chest radiograph findings, clinical responses, and adverse events under blinded conditions, thus increasing its objectivity. In general, there was agreement between the assessments of the independent committees and those of the investigators. The comparator regimen used in this study was selected in response to requests from regulatory authorities after evaluation of earlier studies of moxifloxacin in hospitalized patients with CAP [7, 12] . The combination of a nonantipseudomonal third-generation cephalosporin with levofloxacin is recommended (as the alternative) by the European Respiratory Society for treatment of patients with severe CAP [2] .
The need for well-designed, prospective, randomized trials that compare the effectiveness of broad-spectrum combination therapy with fluoroquinolone monotherapy in hospitalized patients with CAP has been recognized [17] . Several studies have evaluated such regimens with fluoroquinolones other than moxifloxacin [18] [19] [20] [21] ; however, methodological flaws have limited the studies' usefulness in assessing the roles of each treatment in seriously ill patients. Moxifloxacin was investigated previously as monotherapy in hospitalized patients with CAP [7, 11, 12, 22] and was shown to be highly effective in patients who have been infected with macrolide-, penicillin-, or multidrug-resistant pneumococci [23] . The study described here addresses efficacy in patients who are hospitalized because of serious illness, but it should be noted that admission to the ICU was not required for study admission.
In patients with pneumonia who die within 3 days of initiating antibiotic treatment, the cause of death is considered to be the underlying severity of CAP or comorbidities, rather than failure of antibiotic therapy [24] . For this reason, the most pertinent mortality data for the comparison of therapeutic interventions is that for the period 72 h to 30 days after the start of treatment. The mortality rates for the 2 comparator regimens were not significantly different in all strata of severity. Mortality data for all patients in each group and mortality in each PSI class were lower in the present study than were those observed in the large observational Pneumonia Patient Outcome Research Team (PORT) study [25] and comparable to those in the more recent Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE) study [16] . The reasons for this are likely to be the effectiveness of both regimens, and selection of the patients according to predefined eligibility criteria (patients with known, rapidly fatal underlying disease were not eligible for study entry).
In conclusion, sequential intravenous and oral moxifloxacin monotherapy (400 mg once per day) was noninferior to a combination of intravenous ceftriaxone (once per day) plus sequential intravenous and oral levofloxacin (twice per day) for the treatment of hospitalized patients with CAP III-V. There was a good correlation between clinical cure and bacteriological success, and both regimens were safe and well tolerated.
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APPENDIX A. INCLUSION AND EXCLUSION CRITERIA.
Inclusion Criteria
• Radiological confirmation of the presence of infiltrates consistent with bacterial pneumonia.
• All of the following signs and symptoms of pneumonia:
• Fever (core, rectal, or tympanic temperature, у38.5ЊC; or axillary, oral, or cutaneous temperature, у38.0ЊC) or hypothermia (core, rectal, or tympanic temperature, р35.5ЊC; or axillary, oral, cutaneous temperature, р35.0ЊC).
• WBC count, 110,000 cells/mL; у15% immature neutrophils (bands, regardless of WBC count); or WBC count, !4500 cells/mL.
• Two or more of the following signs and symptoms:
cough, purulent sputum production, dyspnea or tachypnea (respiratory rate, 1 20 breaths/min), rigors and chills, chest pain, auscultatory findings on pulmonary examination of rales/crackles, and/or evidence of pulmonary consolidation.
Exclusion Criteria
• Patient pregnant or lactating.
• Hospitalization for 148 h before development of pneumonia or discharge from hospital !30 days before enrollment.
• Receipt of systemic antibacterial therapy for у24 h within 7 days before enrollment, unless treatment failure was deemed to have occurred after receiving an antibacterial regimen that did not contain a fluoroquinolone or a thirdgeneration cephalosporin for у48 h.
• Need for concomitant systemic antibacterial agents.
• Tuberculosis or endemic fungal infection.
• Rapidly fatal underlying disease (death expected within 6 months).
• Structural lung disease (e.g., cystic fibrosis, bronchiectasis, lung cancer, or other conditions predisposing to nosocomial infection) or lung abscess.
• Plural empyema and risk factors for aspiration pneumonia (e.g., recent stroke, head injury, or dementia).
• Neutropenia (absolute neutrophil count, !1000 cells/mL) due to receipt of immunosuppressive therapy or malignancy.
• AIDS (CD4 count, !200 cells/mL, or HIV seropositivity in patients receiving HAART).
• Severe hepatic impairment (Child Pugh classification C).
• Renal failure (creatinine clearance, !10 mL/min) or need for renal dialysis.
• History of epilepsy.
• Glucose-6-phosphate deficiency.
• Uncorrected hypokalemia.
• Known congenital or acquired QT c prolongation.
• Concomitant use of drugs known to increase the QT c interval.
• Known hypersensitivity to study medications.
• Clinically relevant bradycardia.
• Clinically relevant heart failure with reduced ventricular ejection fraction.
• Previous history of symptomatic arrhythmias.
APPENDIX 2.
DEFINITION OF TERMS
Clinical response. At the test-of-cure assessment, clinical response was defined as cure (complete resolution of acute signs and symptoms related to the infection or sufficient improvement such that additional or alternative antimicrobial therapy was not required), failure (insufficient lessening of the signs and symptoms of infection such that additional or alternative antimicrobial therapy was required), or indeterminate. At the follow-up assessment, clinical response was defined as continued cure (resolution of acute signs and symptoms maintained throughout the follow-up period), relapse (reappearance of signs and symptoms requiring reinstitution of an antibacterial therapy), or indeterminate. Bacteriological response. Bacterial responses were classified as eradication, presumed eradication (if no sputum sample was available with a clinical assessment of "cure"), eradication with superinfection (appearance of a new pathogen causing respiratory infection associated with clinical failure), persistence, presumed persistence (if no sputum sample was available for a case classified as "clinical failure"), or indeterminate (bacteriological response to study drug not evaluable).
